Publikasi Scopus 2024 per tanggal 31 Mei 2024 (409 artikel)

Authors

Putri N.D.; Zhafira A.S.; Wicaksana P.; Sinto R.; Hanafi G.; Wiyono L.; Prayitno A.; Karyanti M.R.; Naibaho M.L.; Febrina F.; Sukandar H.; Setiawaty V.; Mursinah M.; Putra A.R.; Wibowo H.; Sundoro J.; Satari H.I.; Oktavia D.; Multihartina P.; Harbuwono D.S.; Hadinegoro S.R.

Author_Full_Names

Putri, Nina Dwi (57200573842); Zhafira, Aqila Sakina (57205515532); Wicaksana, Pratama (57193446457); Sinto, Robert (36099377100); Hanafi, Gryselda (57193511376); Wiyono, Lowilius (57207889054); Prayitno, Ari (57193342301); Karyanti, Mulya Rahma (56290680800); Naibaho, Murni Luciana (59007491000); Febrina, Febrina (59008087000); Sukandar, Hadyana (14523799100); Setiawaty, Vivi (18234212700); Mursinah, Mursinah (57193197814); Putra, Ahmat Rediansya (58569888900); Wibowo, Heri (57217690943); Sundo

Author S Id

57200573842; 57205515532; 57193446457; 36099377100; 57193511376; 57207889054; 57193342301; 56290680800; 59007491000; 59008087000; 14523799100; 18234212700; 57193197814; 58569888900; 57217690943; 49762130000; 57226214366; 57219415909; 56708801900; 36056341600; 57226218772

Title

Immunogenicity and Safety of Half-Dose Heterologous mRNA-1273 Booster Vaccination for Adults Primed with the CoronaVac® and ChAdOx1-S Vaccines for SARS-CoV-2

Year

2024

Source Title

Vaccines

Volume

Issue

Art No

344

Page Start

Page End

Page Count

Cited By

Link

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85191756326&doi=10.3390%2fvaccines12040344&partnerID=40&md5=c828f944ed84018098ac51341c97f9c5

Affiliations

Faculty of Medicine, Universitas Indonesia—Cipto Mangunkusumo Hospital, Jakarta, 10430, Indonesia; Cempaka Putih Public Health Center, Jakarta, 10520, Indonesia; National Institute of Health Research & Development, Jakarta, 14530, Indonesia; Diagnostic and Research Center, Faculty of Medicine, Universitas Indonesia, Jakarta, 10430, Indonesia; The Indonesian Technical Advisory Group on Immunization, Jakarta, 10430, Indonesia; Jakarta Health Agency, Jakarta, 10160, Indonesia; Ministry of Health of Republic of Indonesia, Jakarta, 12750, Indonesia

Authors With Affiliations

Putri N.D., Faculty of Medicine, Universitas Indonesia—Cipto Mangunkusumo Hospital, Jakarta, 10430, Indonesia; Zhafira A.S., Faculty of Medicine, Universitas Indonesia—Cipto Mangunkusumo Hospital, Jakarta, 10430, Indonesia; Wicaksana P., Faculty of Medicine, Universitas Indonesia—Cipto Mangunkusumo Hospital, Jakarta, 10430, Indonesia; Sinto R., Faculty of Medicine, Universitas Indonesia—Cipto Mangunkusumo Hospital, Jakarta, 10430, Indonesia; Hanafi G., Faculty of Medicine, Universitas Indonesia—Cipto Mangunkusumo Hospital, Jakarta, 10430, Indonesia; Wiyono L., Faculty of Medicine, Universitas Indonesia—Cipto Mangunkusumo Hospital, Jakarta, 10430, Indonesia; Prayitno A., Faculty of Medicine, Universitas Indonesia—Cipto Mangunkusumo Hospital, Jakarta, 10430, Indonesia; Karyanti M.R., Faculty of Medicine, Universitas Indonesia—Cipto Mangunkusumo Hospital, Jakarta, 10430, Indonesia; Naibaho M.L., Cempaka Putih Public Health Center, Jakarta, 10520, Indonesia; Febrina F., Cempaka Putih Public Health Center, Jakarta, 10520, Indonesia; Sukandar H., Faculty of Medicine, Universitas Indonesia—Cipto Mangunkusumo Hospital, Jakarta, 10430, Indonesia; Setiawaty V., National Institute of Health Research & Development, Jakarta, 14530, Indonesia; Mursinah M., National Institute of Health Research & Development, Jakarta, 14530, Indonesia; Putra A.R., Diagnostic and Research Center, Faculty of Medicine, Universitas Indonesia, Jakarta, 10430, Indonesia; Wibowo H., Diagnostic and Research Center, Faculty of Medicine, Universitas Indonesia, Jakarta, 10430, Indonesia; Sundoro J., The Indonesian Technical Advisory Group on Immunization, Jakarta, 10430, Indonesia; Satari H.I., Faculty of Medicine, Universitas Indonesia—Cipto Mangunkusumo Hospital, Jakarta, 10430, Indonesia; Oktavia D., Jakarta Health Agency, Jakarta, 10160, Indonesia; Multihartina P., National Institute of Health Research & Development, Jakarta, 14530, Indonesia; Harbuwono D.S., Ministry of Health of Republic of Indonesia, Jakarta, 12750, Indonesia; Hadinegoro S.R., Faculty of Medicine, Universitas Indonesia—Cipto Mangunkusumo Hospital, Jakarta, 10430, Indonesia

Abstract

Coronavirus disease 2019 (COVID-19) has been extensively researched, particularly with regard to COVID-19 vaccines. However, issues with logistics and availability might cause delays in vaccination programs. Thus, the efficacy and safety of half-dose heterologous mRNA should be explored. This was an open-label observational study to evaluate the immunogenicity and safety of half-dose mRNA-1273 as a booster vaccine among adults aged >18 years who underwent a complete primary SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) vaccination regimen with CoronaVac® and ChAdOx1-S. Adverse events (AEs), seropositivity rate, seroconversion, geometric mean titer (GMT) of SARS-CoV-2 antibodies, neutralizing antibodies, and T cells (CD4+ and CD8+) specific for SARS-CoV-2 were analyzed. Two hundred subjects were included in the final analysis, with 100 subjects in each priming vaccine group. Most of the AEs were mild, with systemic manifestations occurring between 1 and 7 days following vaccination. A significant difference was observed in the GMT and seropositivity rate following booster dose administration between the two groups. CD8+/CD3+, IFN (interferon)-producing CD8+, and TNF (tumor necrosis factor)-producing CD8+ cells showed significant increases in both groups. The administration of the half-dose mRNA-1273 booster is safe and effective in increasing protection against SARS-CoV-2 infection. © 2024 by the authors.

Author Keywords

booster; COVID-19; efficacy; half-dose; mRNA; safety; vaccine

Index Keywords

coronavac; elasomeran; lipid nanoparticle; neutralizing antibody; SARS-CoV-2 antibody; tumor necrosis factor; vaxzevria; adult; antibody response; antibody titer; arthralgia; Article; CD8+ T lymphocyte; clinical practice; coronavirus disease 2019; drug efficacy; drug safety; electrochemiluminescence; faintness; fatigue; female; fever; geometric mean titer; headache; human; human experiment; immune response; incidence; malaise; male; middle aged; myalgia; nausea; observational study; open study; pregnancy; seroconversion; Severe acute respiratory syndrome coronavirus 2; structured questionnaire; T lymphocyte; temperature; thorax pain; vaccination; vaccine immunogenicity; vomiting

Funding Details

Ministry of Health of the Republic of Indonesia; Ministry of Education, MOE; Puskesmas Cempaka Putih; Ministry of Education, Culture, Research and Technology of The Republic of Indonesia on the Partnership in Research Indonesia and Melbourne, (PRJ-120/LPDP/2021)

Funding Text

Funding text 1: This research was funded by the Ministry of Health of The Republic of Indonesia with the publication funded by the Indonesia Endowment Fund for Education Agency from the Ministry of Education and the Ministry of Education, Culture, Research and Technology of The Republic of Indonesia on the Partnership in Research Indonesia and Melbourne (funding code PRJ-120/LPDP/2021).; Funding t

Publisher

Multidisciplinary Digital Publishing Institute (MDPI)

Issn

2076393X

Isbn

Pubmed Id

Document Type

Article

Sjr Best Quartile

Sjr

1655

Sjr Rank

1799